{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T12:26:59Z","timestamp":1742646419460},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40266-024-01107-y","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T13:02:19Z","timestamp":1709125339000},"page":"399-406","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults"],"prefix":"10.1007","volume":"41","author":[{"given":"Emily","family":"Schehlein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"3","key":"1107_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262\u20137. https:\/\/doi.org\/10.1136\/bjo.2005.081224.","journal-title":"Br J Ophthalmol"},{"key":"1107_CR2","doi-asserted-by":"publisher","unstructured":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e160. https:\/\/doi.org\/10.1016\/S2214-109X(20)30489-7","DOI":"10.1016\/S2214-109X(20)30489-7"},{"issue":"11","key":"1107_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013.","journal-title":"Ophthalmology"},{"issue":"11","key":"1107_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1001\/archopht.124.11.1625","volume":"124","author":"DS Friedman","year":"2006","unstructured":"Friedman DS, Jampel HD, Mu\u00f1oz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124(11):1625\u201330. https:\/\/doi.org\/10.1001\/archopht.124.11.1625.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1107_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (Chicago, Ill 1960). 2002;120(6):701\u201330.","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"1","key":"1107_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol (Chicago, Ill 1960). 2003;121(1):48\u201356.","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"key":"1107_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.09.009","author":"G Gazzard","year":"2022","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. LiGHT trial: 6-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2022. https:\/\/doi.org\/10.1016\/j.ophtha.2022.09.009.","journal-title":"Ophthalmology"},{"issue":"12","key":"1107_CR8","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41433-021-01595-x","volume":"35","author":"ICF Pereira","year":"2021","unstructured":"Pereira ICF, van de Wijdeven R, Wyss HM, Beckers HJM, den Toonder JMJ. Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions. Eye (Lond). 2021;35(12):3202\u201321. https:\/\/doi.org\/10.1038\/s41433-021-01595-x.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1107_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2020.06.051","volume":"128","author":"S Rathi","year":"2021","unstructured":"Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in glaucoma surgeries performed by glaucoma subspecialists versus nonsubspecialists on medicare beneficiaries from 2008 through 2016. Ophthalmology. 2021;128(1):30\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.051.","journal-title":"Ophthalmology"},{"key":"1107_CR10","unstructured":"AbbVie. Allergan Receives FDA Approval for DURYSTATM. https:\/\/news.abbvie.com\/news\/allergan-press-releases\/allergan-receives-fda-approval-for-durysta-bimatoprost-implant-first-and-only-intracameral-biodegradable-sustained-release-implant-to-lower-intraocular-pressure-in-open-angle-glaucoma-or-ocular-hypertension-patients.htm. Published 2020. Accessed 17 Dec 2023"},{"issue":"12","key":"1107_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","volume":"127","author":"FA Medeiros","year":"2020","unstructured":"Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627\u201341. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.018.","journal-title":"Ophthalmology"},{"issue":"6","key":"1107_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","volume":"37","author":"M Shirley","year":"2020","unstructured":"Shirley M. Bimatoprost implant: first approval. Drugs Aging. 2020;37(6):457\u201362. https:\/\/doi.org\/10.1007\/s40266-020-00769-8.","journal-title":"Drugs Aging"},{"issue":"8","key":"1107_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1089\/jop.2017.0051","volume":"33","author":"MGJ Trese","year":"2017","unstructured":"Trese MGJ, Lewis AW, Blachley TS, Stein JD, Moroi SE. Changing initial glaucoma medical therapy increases healthcare resource utilization. J Ocul Pharmacol Ther. 2017;33(8):591\u20137. https:\/\/doi.org\/10.1089\/jop.2017.0051.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"1107_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0161-6420(99)90147-1","volume":"106","author":"DC Musch","year":"1999","unstructured":"Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106(4):653\u201362.","journal-title":"Ophthalmology"},{"issue":"6","key":"1107_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ajo.2011.05.015","volume":"152","author":"AL Hennessy","year":"2011","unstructured":"Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011;152(6):982\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2011.05.015.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1107_CR16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308\u201316. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.026.","journal-title":"Ophthalmology"},{"issue":"4","key":"1107_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","volume":"152","author":"R Varma","year":"2011","unstructured":"Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515\u201322. https:\/\/doi.org\/10.1016\/j.ajo.2011.06.004.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1107_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/archopht.124.12.1754","volume":"124","author":"DB Rein","year":"2006","unstructured":"Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754\u201360. https:\/\/doi.org\/10.1001\/archopht.124.12.1754.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1107_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/IJG.0000000000000619","volume":"26","author":"EM Schehlein","year":"2017","unstructured":"Schehlein EM, Im LT, Robin AL, Onukwugha E, Saeedi OJ. Nonmedical out-of-pocket patient and companion expenditures associated with glaucoma care. J Glaucoma. 2017;26(4):343\u20138. https:\/\/doi.org\/10.1097\/IJG.0000000000000619.","journal-title":"J Glaucoma"},{"issue":"9","key":"1107_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jamaophthalmol.2015.1671","volume":"133","author":"DM Blumberg","year":"2015","unstructured":"Blumberg DM, Prager AJ, Liebmann JM, Cioffi GA, De Moraes CG. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D. JAMA Ophthalmol. 2015;133(9):985\u201396. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.1671.","journal-title":"JAMA Ophthalmol."},{"issue":"5","key":"1107_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/02713683.2011.562340","volume":"36","author":"WC Stewart","year":"2011","unstructured":"Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391\u20138. https:\/\/doi.org\/10.3109\/02713683.2011.562340.","journal-title":"Curr Eye Res"},{"issue":"5","key":"1107_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350\u20135. https:\/\/doi.org\/10.1097\/IJG.0b013e31815c5f4f.","journal-title":"J Glaucoma"},{"issue":"2","key":"1107_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1006\/exer.2002.2009","volume":"75","author":"M Honjo","year":"2002","unstructured":"Honjo M, Inatani M, Kido N, et al. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res. 2002;75(2):135\u201342. https:\/\/doi.org\/10.1006\/exer.2002.2009.","journal-title":"Exp Eye Res"},{"key":"1107_CR24","first-page":"32","volume":"8","author":"JL Vittitow","year":"2002","unstructured":"Vittitow JL, Garg R, Rowlette L-LS, Epstein DL, O\u2019Brien ET, Borr\u00e1s T. Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis. 2002;8:32\u201344.","journal-title":"Mol Vis."},{"issue":"2\u20133","key":"1107_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/jop.2013.0192","volume":"30","author":"H Gong","year":"2014","unstructured":"Gong H, Yang C-YC. Morphological and hydrodynamic correlations with increasing outflow facility by rho-kinase inhibitor Y-27632. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2014;30(2\u20133):143\u201353. https:\/\/doi.org\/10.1089\/jop.2013.0192.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther."},{"key":"1107_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.04.002","author":"G Li","year":"2016","unstructured":"Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016. https:\/\/doi.org\/10.1016\/j.ejphar.2016.04.002.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1107_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.exer.2004.08.029","volume":"80","author":"PV Rao","year":"2005","unstructured":"Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res. 2005;80(2):197\u2013206. https:\/\/doi.org\/10.1016\/j.exer.2004.08.029.","journal-title":"Exp Eye Res"},{"key":"1107_CR28","doi-asserted-by":"publisher","unstructured":"Abu-Hassan DW, Acott TS, Kelley MJ. The Trabecular Meshwork: A Basic Review of Form and Function. J Ocul Biol. 2014;2(1). https:\/\/doi.org\/10.13188\/2334-2838.1000017","DOI":"10.13188\/2334-2838.1000017"},{"issue":"7","key":"1107_CR29","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"H Tokushige","year":"2007","unstructured":"Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48(7):3216\u201322. https:\/\/doi.org\/10.1167\/iovs.05-1617.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"1107_CR30","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"57","author":"R Ren","year":"2016","unstructured":"Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197\u2013209. https:\/\/doi.org\/10.1167\/iovs.16-20189.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1107_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/jop.2017.0138","volume":"34","author":"A Kazemi","year":"2018","unstructured":"Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2018;34(5):380\u20136. https:\/\/doi.org\/10.1089\/jop.2017.0138.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther."},{"issue":"1","key":"1107_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","volume":"24","author":"R-F Wang","year":"2015","unstructured":"Wang R-F, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51\u20134. https:\/\/doi.org\/10.1097\/IJG.0b013e3182952213.","journal-title":"J Glaucoma"},{"issue":"12","key":"1107_CR33","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1167\/iovs.07-0878","volume":"48","author":"M Honjo","year":"2007","unstructured":"Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48(12):5549\u201357. https:\/\/doi.org\/10.1167\/iovs.07-0878.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"1107_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3109\/02713683.2011.599106","volume":"36","author":"H Tokushige","year":"2011","unstructured":"Tokushige H, Waki M, Takayama Y, Tanihara H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011;36(10):964\u201370. https:\/\/doi.org\/10.3109\/02713683.2011.599106.","journal-title":"Curr Eye Res"},{"issue":"3","key":"1107_CR35","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1167\/iovs.15-18586","volume":"57","author":"N Okumura","year":"2016","unstructured":"Okumura N, Okazaki Y, Inoue R, et al. Effect of the rho-associated kinase inhibitor eye drop (Ripasudil) on corneal endothelial wound healing. Invest Ophthalmol Vis Sci. 2016;57(3):1284\u201392. https:\/\/doi.org\/10.1167\/iovs.15-18586.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1107_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/175163","volume":"2010","author":"R Arita","year":"2010","unstructured":"Arita R, Hata Y, Ishibashi T. ROCK as a therapeutic target of diabetic retinopathy. J Ophthalmol. 2010;2010: 175163. https:\/\/doi.org\/10.1155\/2010\/175163.","journal-title":"J Ophthalmol"},{"key":"1107_CR37","unstructured":"FDA Approves Rhopressa. https:\/\/www.drugs.com\/newdrugs\/aerie-pharmaceuticals-announces-u-s-fda-approval-rhopressa-netarsudil-ophthalmic-solution-0-02-4663.html. Published 2017. Accessed 17 Dec 2023"},{"key":"1107_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327. https:\/\/doi.org\/10.1016\/j.ajo.2017.11.019.","journal-title":"Am J Ophthalmol"},{"key":"1107_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97\u2013104. https:\/\/doi.org\/10.1016\/j.ajo.2019.03.002.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1107_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","volume":"122","author":"J Bacharach","year":"2015","unstructured":"Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2014.08.022.","journal-title":"Ophthalmology"},{"key":"1107_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100689","volume":"98","author":"AT Pham","year":"2023","unstructured":"Pham AT, Bradley C, Casey C, Jampel HD, Ramulu PY, Yohannan J. Effectiveness of netarsudil versus brimonidine in eyes already being treated with glaucoma medications at a single academic tertiary care practice: a comparative study. Curr Ther Res Clin Exp. 2023;98: 100689. https:\/\/doi.org\/10.1016\/j.curtheres.2022.100689.","journal-title":"Curr Ther Res Clin Exp"},{"key":"1107_CR42","unstructured":"Aerie Pharmaceuticals Receives FDA Approval of Rocklatan for Reduction of IOP. https:\/\/eyewire.news\/articles\/aerie-pharmaceuticals-receives-fda-approval-of-rocklatan-for-reduction-of-iop\/?c4src=article:infinite-scroll. Published 2019. Accessed 17 Dec 2023"},{"issue":"3","key":"1107_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bjophthalmol-2015-306778","volume":"100","author":"RA Lewis","year":"2016","unstructured":"Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100(3):339\u201344. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306778. Accessed 17 Dec 2023","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"1107_CR44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ogla.2020.05.008","volume":"3","author":"JW Brubaker","year":"2020","unstructured":"Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327\u201338. https:\/\/doi.org\/10.1016\/j.ogla.2020.05.008.","journal-title":"Ophthalmol Glaucoma."},{"issue":"5","key":"1107_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","volume":"2","author":"TR Walters","year":"2019","unstructured":"Walters TR, Ahmed IIK, Lewis RA, et al. Once-Daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2(5):280\u20139. https:\/\/doi.org\/10.1016\/j.ogla.2019.03.007.","journal-title":"Ophthalmol Glaucoma."},{"issue":"4","key":"1107_CR46","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","volume":"37","author":"S Asrani","year":"2020","unstructured":"Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620\u201331. https:\/\/doi.org\/10.1007\/s12325-020-01277-2.","journal-title":"Adv Ther"},{"key":"1107_CR47","unstructured":"LLC MS. Market Scope 2022 Glaucoma Pharmaceuticals Report. Missouri; 2022."},{"issue":"4","key":"1107_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731\u20136. https:\/\/doi.org\/10.1016\/j.ajo.2013.05.016.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1107_CR49","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26-34. https:\/\/doi.org\/10.1111\/aos.12829.","journal-title":"Acta Ophthalmol."},{"issue":"6","key":"1107_CR50","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.4103\/ijo.IJO_3145_21","volume":"70","author":"J Jethva","year":"2022","unstructured":"Jethva J, Bhagat P, Prajapati K, Tank G. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy. Indian J Ophthalmol. 2022;70(6):2020\u20133. https:\/\/doi.org\/10.4103\/ijo.IJO_3145_21.","journal-title":"Indian J Ophthalmol"},{"key":"1107_CR51","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.2147\/OPTH.S318897","volume":"15","author":"M Naik","year":"2021","unstructured":"Naik M, Kapur M, Gupta V, Sethi H, Srivastava K. Ripasudil endgame: role of rho-kinase inhibitor as a last-ditch-stand towards maximally tolerated medical therapy to a patient of advanced glaucoma. Clin Ophthalmol. 2021;15:2683\u201392. https:\/\/doi.org\/10.2147\/OPTH.S318897.","journal-title":"Clin Ophthalmol"},{"key":"1107_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.exer.2016.07.001","volume":"149","author":"A Futakuchi","year":"2016","unstructured":"Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107\u201315. https:\/\/doi.org\/10.1016\/j.exer.2016.07.001.","journal-title":"Exp Eye Res"},{"issue":"18","key":"1107_CR53","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74(18):2211\u20135. https:\/\/doi.org\/10.1007\/s40265-014-0333-2.","journal-title":"Drugs"},{"issue":"12","key":"1107_CR54","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1167\/iovs.15-17887","volume":"56","author":"N Okumura","year":"2015","unstructured":"Okumura N, Okazaki Y, Inoue R, et al. Rho-associated kinase inhibitor eye drop (Ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci. 2015;56(12):7560\u20137. https:\/\/doi.org\/10.1167\/iovs.15-17887.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1107_CR55","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-018-3945-5","volume":"256","author":"E Chihara","year":"2018","unstructured":"Chihara E, Dimitrova G, Chihara T. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine. Graefe\u2019s Arch Clin Exp Ophthalmol Albr von Graefes Arch fur Klin und Exp Ophthalmol. 2018;256(7):1257\u201364. https:\/\/doi.org\/10.1007\/s00417-018-3945-5.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol Albr von Graefes Arch fur Klin und Exp Ophthalmol."},{"issue":"11","key":"1107_CR56","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1167\/iovs.13-13842","volume":"55","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Maruyama K, Himori N, et al. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci. 2014;55(11):7126\u201336. https:\/\/doi.org\/10.1167\/iovs.13-13842.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1107_CR57","doi-asserted-by":"publisher","first-page":"7079645","DOI":"10.1155\/2017\/7079645","volume":"2017","author":"Y Kaneko","year":"2017","unstructured":"Kaneko Y, Ohta M, Isobe T, Nakamura Y, Mizuno K. Additive intraocular pressure-lowering effects of ripasudil with glaucoma therapeutic agents in rabbits and monkeys. J Ophthalmol. 2017;2017:7079645. https:\/\/doi.org\/10.1155\/2017\/7079645.","journal-title":"J Ophthalmol"},{"key":"1107_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.11.017","author":"H Tanihara","year":"2022","unstructured":"Tanihara H, Yamamoto T, Aihara M, et al. Ripasudil-brimonidine Fixed-dose combination vs. ripasudil or brimonidine; two phase 3 randomized clinical trials. Am J Ophthalmol. 2022. https:\/\/doi.org\/10.1016\/j.ajo.2022.11.017.","journal-title":"Am J Ophthalmol."},{"issue":"7","key":"1107_CR59","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Additive Intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755\u201361. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.0525.","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"1107_CR60","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1111\/aos.14949","volume":"100","author":"A Ha","year":"2022","unstructured":"Ha A, Kim YK, Jeoung JW, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study. Acta Ophthalmol. 2022;100(2):e470\u20137. https:\/\/doi.org\/10.1111\/aos.14949.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"1107_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"H Tanihara","year":"2008","unstructured":"Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol (Chicago, Ill 1960). 2008;126(3):309\u201315. https:\/\/doi.org\/10.1001\/archophthalmol.2007.76.","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"5","key":"1107_CR62","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1111\/aos.12641","volume":"93","author":"T Inoue","year":"2015","unstructured":"Inoue T, Tanihara H, Tokushige H, Araie M. Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 2015;93(5):e393\u20135. https:\/\/doi.org\/10.1111\/aos.12641.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"1107_CR63","first-page":"4714","volume":"59","author":"Y Takahashi","year":"2018","unstructured":"Takahashi Y, Inoue T, Imai S, Otsuka T, Arakawa R, Naito A. WP-1303 (H-1129), a novel antiglaucoma agent, lowers intraocular pressure by increasing conventional outflow in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2018;59(9):4714.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1107_CR64","unstructured":"CRO C. Announcement of the Discontinuation of Development in Japan with WP-1303 (H-1129). https:\/\/www.cmocro.com\/news_detail\/Announcement+of+the+Discontinuation+of+Development+in+Japan+\/418503\/index.html. Published 2019. Accessed 17 Dec 2023"},{"issue":"2","key":"1107_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/iovs.64.2.7","volume":"64","author":"R Ren","year":"2023","unstructured":"Ren R, Humphrey AA, Kopczynski C, Gong H. Rho kinase inhibitor AR-12286 reverses steroid-induced changes in intraocular pressure, effective filtration areas, and morphology in mouse eyes. Invest Ophthalmol Vis Sci. 2023;64(2):7. https:\/\/doi.org\/10.1167\/iovs.64.2.7.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1107_CR66","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00063030-200721030-00004","volume":"21","author":"VP Rao","year":"2007","unstructured":"Rao VP, Epstein DL. Rho GTPase\/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21(3):167\u201377. https:\/\/doi.org\/10.2165\/00063030-200721030-00004.","journal-title":"BioDrugs"},{"issue":"5","key":"1107_CR67","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajo.2015.01.026","volume":"159","author":"B Levy","year":"2015","unstructured":"Levy B, Ramirez N, Novack GD, Kopczynski C. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159(5):980-5.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.026.","journal-title":"Am J Ophthalmol"},{"key":"1107_CR68","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","volume":"207","author":"S Asrani","year":"2019","unstructured":"Asrani S, Robin AL, Serle JB, et al. Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248\u201357. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.016.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1107_CR69","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288\u201395. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.323.","journal-title":"JAMA Ophthalmol."},{"key":"1107_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306778","author":"RA Lewis","year":"2015","unstructured":"Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2015. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306778.","journal-title":"Br J Ophthalmol."},{"issue":"2","key":"1107_CR71","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1167\/iovs.12-10583","volume":"54","author":"JJ Arnold","year":"2013","unstructured":"Arnold JJ, Hansen MS, Gorman GS, et al. The effect of rho-associated kinase inhibition on the ocular penetration of timolol maleate. Invest Ophthalmol Vis Sci. 2013;54(2):1118\u201326. https:\/\/doi.org\/10.1167\/iovs.12-10583.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01107-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01107-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01107-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T13:02:31Z","timestamp":1715691751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01107-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01107-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"7 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None. No sources of financial assistance were used to assist with the preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Schehlein consults for Allergan, Glaukos, and Perceptron Health and holds stock options in Perceptron Health. Dr Robin has stock options in Perfuse Therapeutics, Nanodropper, and was an employee of the American Glaucoma Society.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"The first draft of the manuscript was written by Emily Schehlein and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}